It still feels really weird not to be heading off to Chicago O’Hare in a few weeks

Every year at ASCO we take a quick look at various trials which jump out from the first pass of the data once the abstracts become available then follow up with more in-depth previews later.

There are some winners and losers in this mix, as well as some hidden gems and informative analyses to think about.

So without further ado – what stood out this year for better or worse?

To learn more about our pre ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by